Junaya

Dienogest / Ethinylestradiol, the active ingredients in Junaya, are a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus and the endometrium. GNH USA supplies Junaya as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Junaya, a combined oral contraceptive, is used to prevent pregnancy by suppressing ovulation and modifying the uterine environment.

Prevention of pregnancy: provides reliable contraception for women of childbearing potential. Regulation of menstrual cycles: helps achieve more predictable bleeding patterns. Acne management: reduces androgen‑related acne in women using hormonal contraception. Treatment of dysmenorrhea: alleviates painful menstrual cramps associated with ovulatory cycles.

Common Side Effects: - Nausea or mild gastrointestinal upset. - Breast tenderness or enlargement. - Headache or migraine onset. - Breakthrough or spotting bleeding. - Weight fluctuation or fluid retention. - Mood changes or irritability.

Serious or Rare Side Effects: - Venous thromboembolism (deep vein thrombosis, pulmonary embolism). - Arterial thrombosis (stroke, myocardial infarction). - Severe hypertension. - Hepatic adenoma or tumor. - Anaphylactic or severe allergic reaction. - Visual disturbances indicating retinal vascular events.

Junaya requires careful assessment before initiation and during therapy. - Contraindicated in pregnancy: category X, must not be used. - Avoid in women with a history of thromboembolic disease or clotting disorders. - Do not use in smokers over 35 years of age due to increased cardiovascular risk. - Monitor blood pressure regularly; discontinue if hypertension develops. - Assess liver function; avoid in severe hepatic impairment. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Junaya may interact with several drug classes, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) may markedly reduce contraceptive effectiveness. - Concurrent use with anticoagulants can increase bleeding risk. - Certain antiretrovirals (e.g., protease inhibitors) may alter hormone levels.

Moderate Interactions (Monitor Closely): - SSRIs or other antidepressants may heighten mood‑related side effects. - Antihypertensive agents may require dose adjustment due to estrogen‑induced fluid retention. - Herbal supplements such as St. John's wort can diminish contraceptive efficacy. - Non‑steroidal anti‑inflammatory drugs may increase risk of gastrointestinal irritation.